Literature DB >> 7868156

Oligosaccharides and discordant xenotransplantation.

D K Cooper1, E Koren, R Oriol.   

Abstract

The initiating factor in the hyperacute rejection of pig organs by human or non-human primates is believed to be related to the presence of preformed "natural" antibodies in the host. In 1991, we demonstrated that human anti-pig antibodies were IgG, IgM and IgA and bound most strongly to oligosaccharides with an alpha galactose (alpha Gal) terminal residue. These included (i) alpha Gal-R (alpha galactose), (ii) alpha Gall-3 beta Gal-R (B disaccharide), (iii) alpha Gall-3 beta Gall-4 beta GlcNAc-R (linear B type 2 trisaccharide) and (iv) alpha Gall-3 beta Gall-4 beta Glc-R (linear B type 6 trisaccharide) where R is (CH2) 8COOCH3. In vitro studies using both the chromium release assay and a live/dead staining technique demonstrated that the cytotoxicity of human sera towards pig cells can be significantly reduced or abolished by immunoadsorption of the serum with immunoaffinity columns of an alpha Gal structure, particularly those with an alpha 1-3 linkage, and not by a large selection of other carbohydrates. Similarly, human anti-pig antibodies can be largely inhibited or "neutralized" by the addition of an alpha 1-3Gal di- or trisaccharide to the serum. Staining of pig vascular endothelium utilizing a panel of carbohydrate-specific lectins and immunoaffinity antibodies demonstrated the presence of three different carbohydrate epitopes, namely (i) alpha Gall-3 beta Gall-4 beta GlcNAc-R (linear B type 2 trisaccharide (ii) alpha NeuAc2-3 beta Gall-4 beta GlcNAc-R (sialyl-N-acetyllactosamine), and (iii) beta Gall-4 beta GlcNAc-R (N-acetyllactosamine). We have investigated organs from several breeds of pig and have concluded that the alpha Gal epitope is either monomorphic or at least has a high incidence in porcine species, since we have not found any pig negative for this antigen. Human vascular endothelial cells have at their surface the same lactosamine-ended precursor and sialylated chains as pigs, but instead of terminal alpha Gal they express the fucosylated polymorphic ABH histo-blood group epitopes. As we have found no evidence that human or baboon plasma contain antibodies directed against sialic acid or lactosamine, and as human tissues contain both of these carbohydrates, it seems unlikely that either of these epitopes plays a role in the vascular rejection that takes place when pig organs are transplanted into primates. Unfortunately, the alpha Gal disaccharide and trisaccharides were not available to us in the large quantities required for extracorporeal immunoadsorption or continuous intravenous infusion in adult baboons.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868156     DOI: 10.1111/j.1600-065x.1994.tb00871.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  35 in total

1.  Hepatic and intestinal transplantation at the University of Pittsburgh.

Authors:  K Abu-Elmagd; J Fung; J Reyes; A Rao; A Jain; G Mazariegos; W Marsh; J Madariaga; I Dvorchik; J Bueno; J Rogers; J McMichael; F Dodson; H Vargus; J Martin; A Slivka; V Balan; R Corry; J Rakela; N Murase; J Demetris; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1998

2.  Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase.

Authors:  A Sharma; J Okabe; P Birch; S B McClellan; M J Martin; J L Platt; J S Logan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Xenotransplantation: progress and promise. Interview by Clare Thompson.

Authors:  H Y Vanderpool
Journal:  BMJ       Date:  1999-11-13

Review 4.  An update on xenotransplantation.

Authors:  E Cozzi; M Seveso; S Hutabba; S Fabris; L Cavicchioli; E Ancona
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

5.  Xenotransplantation: progress and promise.

Authors:  H Y Vanderpool
Journal:  West J Med       Date:  1999-11

Review 6.  Clinical xenotransplantation: past, present and future.

Authors:  S Taniguchi; D K Cooper
Journal:  Ann R Coll Surg Engl       Date:  1997-01       Impact factor: 1.891

7.  Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer.

Authors:  Andreas G Katopodis; Richard G Warner; Rudolf O Duthaler; Markus B Streiff; Armin Bruelisauer; Olivier Kretz; Birgit Dorobek; Elke Persohn; Hendrik Andres; Alain Schweitzer; Gebhard Thoma; Willy Kinzy; Valerie F J Quesniaux; Emanuele Cozzi; Hugh F S Davies; Rafael Mañez; David White
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 8.  The yeast expression system for recombinant glycosyltransferases.

Authors:  M Malissard; S Zeng; E G Berger
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

Review 9.  Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization.

Authors:  Maelene L Wong; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

Review 10.  Modifying the sugar icing on the transplantation cake.

Authors:  David K C Cooper
Journal:  Glycobiology       Date:  2016-03-01       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.